### ü´Å Pulmonology: Variable Intrathoracic Airway Obstruction Diagnosis

#### ‚úÖ True Statements
1. **Variable intrathoracic airway obstruction** produces a **flow-volume curve with an expiratory plateau**.
2. The term **intrathoracic** in variable intrathoracic airway obstruction refers to the **airway below the thoracic inlet** where pleural pressure changes are transmitted.
3. In **variable intrathoracic airway obstruction**, **flow is impaired during expiration** because **positive pleural pressure during forced expiration narrows the intrathoracic airway**.
4. In **variable intrathoracic airway obstruction**, **flow is preserved during inspiration** because **negative pleural pressure during forced inspiration widens the intrathoracic airway**.
5. Causes of **variable intrathoracic airway obstruction** include **localized tumors of the lower trachea or mainstem bronchus**, a **large bronchogenic cyst**, **large mediastinal adenopathy**, **large thyroid goiter**, and **tracheobronchomalacia**.

#### üí¨ Extra
1. The expiratory plateau represents the hallmark physiologic pattern distinguishing intrathoracic obstruction from other flow-volume curve abnormalities.

#### üè∑Ô∏è Tags
#Pulmonology #AmbulatoryCare #AirwayObstruction #FlowVolumeLoop

#### üìö Reference
MKSAP 19 Pulmonary & Critical Care Medicine. American College of Physicians.

#### üÜî Question ID
PMVDX24005

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Pulmonary Diagnostic Tests, Pulmonary Function Testing, Pulmonary Function Testing Interpretation

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Pulmonary Function Testing Interpretation
1. Pulmonary function testing interpretation classifies abnormal results as **obstructive**, **restrictive**, or **mixed obstructive/restrictive**, and assesses the **severity of impairment**.
2. A **reduced forced expiratory volume in 1 second (FEV‚ÇÅ)/forced vital capacity (FVC) ratio** is consistent with **obstructive lung disease**.
3. The **American Thoracic Society (ATS)** and **European Respiratory Society (ERS)** define a reduced FEV‚ÇÅ/FVC ratio as **below the lower limit of normal**.
4. The **Global Initiative for Chronic Obstructive Lung Disease (GOLD)** defines a reduced FEV‚ÇÅ/FVC ratio as **below 0.70 on a postbronchodilator test**.
5. The 2021 **ATS/ERS technical standard** defines **bronchodilator responsiveness** as an **increase from baseline in FEV‚ÇÅ, FVC, or both of at least 10% relative to the predicted value**.
6. Many pulmonary function laboratories continue to use the **former thresholds** of a **12% and 200 mL increase** to define a significant bronchodilator response.
7. Measurement of **lung volumes** may help assess obstructive lung disease but is **not required for diagnosis**.
8. Elevation of **total lung capacity (TLC)** or **residual volume (RV)** to **‚â•120% of predicted** indicates **hyperinflation and air trapping**, which is common in **severe chronic obstructive pulmonary disease (COPD)**.
9. If **FEV‚ÇÅ or FVC is reduced** and the **FEV‚ÇÅ/FVC ratio is ‚â•0.70**, the pattern may be interpreted as **restrictive**, but measurement of **TLC** is needed to confirm restriction.
10. A **TLC <80% of predicted (or below the lower limit of normal)** confirms a **restrictive ventilatory defect**.
11. Some patients have **mixed obstructive and restrictive patterns**, such as those with **combined pulmonary fibrosis and emphysema**.
12. **Obesity** can reduce **FEV‚ÇÅ** and **FVC** while preserving the **FEV‚ÇÅ/FVC ratio**, and may cause modest reductions in **TLC** and **expiratory reserve volume**.
13. **Diffusing capacity of the lungs for carbon monoxide (DLCO)** is reduced in conditions that **destroy, infiltrate, or remove alveolar-capillary units**, including **COPD**, **diffuse parenchymal lung disease**, and **lung resection**.
14. **DLCO** is also reduced in conditions that compromise alveolar-capillary function, including **pulmonary parenchymal and vascular disorders**.
15. **DLCO** is increased in conditions that **increase pulmonary capillary blood volume**, such as **pulmonary alveolar hemorrhage**, **left-to-right shunt**, and **asthma**.
16. The **flow-volume loop** is a graphical representation of **maximal inspiratory and expiratory flow (Y-axis)** against **volume (X-axis)**.
17. The **shape of the spirometric flow-volume loop** helps differentiate **obstructive from restrictive patterns** and can suggest the **anatomic location of airway obstruction**.

#### üí¨ Extra
5. The new ATS/ERS criteria emphasize changes relative to the predicted value rather than absolute changes.
6. The 12% and 200 mL thresholds remain widely used in clinical practice despite updates.
8. Hyperinflation and air trapping reflect advanced airflow limitation and are hallmarks of severe COPD.
12. Obesity-related reductions are due to altered chest wall mechanics rather than intrinsic lung pathology.
15. Increased DLCO reflects enhanced pulmonary blood volume, not improved alveolar-capillary membrane function.

#### üè∑Ô∏è Tags
#Pulmonology #PulmonaryFunctionTesting #ObstructiveLungDisease #RestrictiveLungDisease #COPD #DLCO #FlowVolumeLoop

---

#### üóæ Supplemental HTML Table(s)
<table>
  <caption><strong>Characterization of Impairment Severity in Pulmonary Function Tests</strong></caption>
  <thead>
    <tr>
      <th>Test Result (% of Predicted)</th>
      <th>Severity of Impairment</th>
    </tr>
  </thead>
  <tbody>
    <tr><td colspan="2"><strong>FEV<sub>1</sub></strong></td></tr>
    <tr><td>70-79</td><td>Mild</td></tr>
    <tr><td>60-69</td><td>Moderate</td></tr>
    <tr><td>50-59</td><td>Moderately severe</td></tr>
    <tr><td>35-49</td><td>Severe</td></tr>
    <tr><td>&lt;35</td><td>Very severe</td></tr>
    <tr><td colspan="2"><strong>D<sub>LCO</sub></strong></td></tr>
    <tr><td>&lt;LLN but &gt;60</td><td>Mild</td></tr>
    <tr><td>40-60</td><td>Moderate</td></tr>
    <tr><td>&lt;40</td><td>Severe</td></tr>
  </tbody>
</table>
<p><em>LLN = lower limit of normal (fifth percentile of healthy never-smokers).</em></p>
<p><em>Reproduced with permission of the ¬© ERS 2025 from Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:957. PMID: 16264058 doi:10.1183/09031936.05.00035205</em></p>

#### ‚úÖ True Statements (from Table: Characterization of Impairment Severity in Pulmonary Function Tests)
1. An FEV1 of 70% to 79% of predicted indicates **mild impairment**.
2. An FEV1 of 60% to 69% of predicted indicates **moderate impairment**.
3. An FEV1 of 50% to 59% of predicted indicates **moderately severe impairment**.
4. An FEV1 of 35% to 49% of predicted indicates **severe impairment**.
5. An FEV1 less than 35% of predicted indicates **very severe impairment**.
6. A diffusing capacity of the lung for carbon monoxide (Dlco) below the lower limit of normal but greater than 60% indicates **mild impairment**.
7. A Dlco of 40% to 60% of predicted indicates **moderate impairment**.
8. A Dlco less than 40% of predicted indicates **severe impairment**.

#### üí¨ Optional Extra(s)
6. The lower limit of normal for Dlco corresponds to the fifth percentile of healthy never-smokers.

---

#### üñºÔ∏è Supplemental Figures
<figure>
  <img src="Diagnose variable intrathoracic airway obstruction on the basis of a flow-volume curve.jpg" alt="Diagnose variable intrathoracic airway obstruction on the basis of a flow-volume curve.jpg">
  <figcaption><strong>Figure: Flow-volume curve in variable intrathoracic airway obstruction</strong>.</figcaption>
</figure>

<figure>
  <img src="Classic Flow-Volume Loops on Spirometry.svg" alt="Classic Flow-Volume Loops on Spirometry.svg">
  <figcaption><strong>Figure: Classic Flow-Volume Loops on Spirometry</strong>.</figcaption>
</figure>